SG10201810825YA - Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same - Google Patents
Histidine engineered light chain antibodies and genetically modified non-human animals for generating the sameInfo
- Publication number
- SG10201810825YA SG10201810825YA SG10201810825YA SG10201810825YA SG10201810825YA SG 10201810825Y A SG10201810825Y A SG 10201810825YA SG 10201810825Y A SG10201810825Y A SG 10201810825YA SG 10201810825Y A SG10201810825Y A SG 10201810825YA SG 10201810825Y A SG10201810825Y A SG 10201810825YA
- Authority
- SG
- Singapore
- Prior art keywords
- light chain
- genetically modified
- modified non
- histidine
- human
- Prior art date
Links
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 title abstract 4
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 abstract 3
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 abstract 3
- 108020004705 Codon Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 210000004602 germ cell Anatomy 0.000 abstract 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
HISTIDINE ENGINEERED LIGHT CHAIN ANTIBODIES AND GENETICALLY MODIFIED NON-HUMAN ANIMALS FOR GENERATING THE SAME A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of pH dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses human immunoglobulin light chain variable domains derived from a limited repertoire of human immunoglobulin light chain variable gene segments that comprise histidine modifications in their germline sequence. Methods of making non-human animals that express antibodies comprising histidine residues encoded by histidine codons introduced into immunoglobulin light chain nucleotide sequences are provided. [No Figure]
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/030,424 US20140013456A1 (en) | 2012-03-16 | 2013-09-18 | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201810825YA true SG10201810825YA (en) | 2019-01-30 |
Family
ID=51663490
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201601272YA SG11201601272YA (en) | 2013-09-18 | 2014-09-18 | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
| SG10201810825YA SG10201810825YA (en) | 2013-09-18 | 2014-09-18 | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201601272YA SG11201601272YA (en) | 2013-09-18 | 2014-09-18 | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
Country Status (25)
| Country | Link |
|---|---|
| EP (2) | EP3046412B1 (en) |
| JP (3) | JP6621750B2 (en) |
| KR (2) | KR102150414B1 (en) |
| CN (2) | CN111019953A (en) |
| AU (2) | AU2014323527B2 (en) |
| BR (1) | BR112016005912A2 (en) |
| CA (1) | CA2922892C (en) |
| CY (1) | CY1121798T1 (en) |
| DK (1) | DK3046412T3 (en) |
| ES (2) | ES2738679T3 (en) |
| HK (1) | HK1225913A1 (en) |
| HR (1) | HRP20191233T1 (en) |
| HU (1) | HUE044747T2 (en) |
| IL (2) | IL244226B (en) |
| LT (1) | LT3046412T (en) |
| MX (1) | MX362904B (en) |
| MY (1) | MY191512A (en) |
| PL (1) | PL3046412T3 (en) |
| PT (1) | PT3046412T (en) |
| RS (1) | RS59003B1 (en) |
| RU (2) | RU2019121863A (en) |
| SG (2) | SG11201601272YA (en) |
| SI (1) | SI3046412T1 (en) |
| TR (1) | TR201909967T4 (en) |
| WO (1) | WO2015042250A1 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140093496A1 (en) | 2011-02-25 | 2014-04-03 | Chugai Seiyaku Kabushiki Kaisha | Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY |
| JP6322411B2 (en) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | Antigen-binding molecules that promote the disappearance of antigens with multiple physiological activities |
| US20150056182A1 (en) | 2011-11-30 | 2015-02-26 | Chugai Seiyaku Kabushiki Kaisha | Drug containing carrier into cell for forming immune complex |
| TWI717591B (en) | 2012-08-24 | 2021-02-01 | 日商中外製藥股份有限公司 | Fcγ riib-specific fc region variant |
| ES2876009T3 (en) | 2012-12-27 | 2021-11-11 | Chugai Pharmaceutical Co Ltd | Heterodimerized polypeptide |
| CA2908350C (en) | 2013-04-02 | 2023-08-08 | Futa Mimoto | Fc region variant |
| MA41294A (en) | 2014-12-19 | 2017-11-08 | Chugai Pharmaceutical Co Ltd | ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING FC REGION VARIANTS, AND METHODS OF USE |
| WO2016125495A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
| US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| RU2766112C2 (en) | 2016-08-05 | 2022-02-08 | Чугаи Сейяку Кабусики Кайся | Composition for prevention or treatment of il-8-related diseases |
| US20220090125A1 (en) * | 2018-12-21 | 2022-03-24 | Compass Therapeutics Llc | Transgenic mouse expressing common human light chain |
| EP4075965A1 (en) * | 2019-12-18 | 2022-10-26 | Bristol-Myers Squibb Company | Bcr transgenic mice with a common leader sequence |
| AU2021342159A1 (en) | 2020-09-11 | 2023-03-02 | Regeneron Pharmaceuticals, Inc. | Identification and production of antigen-specific antibodies |
| IL303626A (en) | 2020-12-16 | 2023-08-01 | Regeneron Pharma | Mice expressing humanized fc alpha receptors |
| CN114568343B (en) * | 2022-03-11 | 2023-04-07 | 成都合拓创展生物科技有限公司 | Headwear for preparing eye disease model and application thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6774279B2 (en) | 1997-05-30 | 2004-08-10 | Carnegie Institution Of Washington | Use of FLP recombinase in mice |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7294754B2 (en) | 2004-10-19 | 2007-11-13 | Regeneron Pharmaceuticals, Inc. | Method for generating an animal homozygous for a genetic modification |
| WO2007117410A2 (en) * | 2006-03-31 | 2007-10-18 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| SI2041177T1 (en) | 2006-06-02 | 2012-03-30 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| CN103251948A (en) * | 2008-04-11 | 2013-08-21 | 中外制药株式会社 | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| AU2009313389A1 (en) * | 2008-11-06 | 2010-05-14 | Alexion Pharmaceuticals, Inc. | Engineered antibodies with reduced immunogenicity and methods of making |
| TWI507525B (en) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| WO2011008096A1 (en) | 2009-07-16 | 2011-01-20 | Wageningen Universiteit | Regulation of zinc deficiency and tolerance in plants |
| RU2425880C2 (en) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Method of producing transgene mice |
| CN102803491A (en) * | 2010-01-21 | 2012-11-28 | 奥克西雷恩英国有限公司 | Methods and compositions for displaying a poypeptide on a yeast cell surface |
| US20130185821A1 (en) | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| RS59001B1 (en) | 2010-02-08 | 2019-08-30 | Regeneron Pharma | Common light chain mouse |
| US20120021409A1 (en) * | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| SG183867A1 (en) * | 2010-03-11 | 2012-10-30 | Rinat Neuroscience Corp | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
| ES2576928T3 (en) * | 2010-06-22 | 2016-07-12 | Regeneron Pharmaceuticals, Inc. | Mice expressing a light chain with the human lambda variable and mouse constant regions |
| AU2011331129B2 (en) * | 2010-11-19 | 2016-10-06 | Morphosys Ag | A collection and methods for its use |
| KR102528622B1 (en) * | 2011-09-30 | 2023-05-04 | 추가이 세이야쿠 가부시키가이샤 | Ion concentration-dependent binding molecule library |
| US20140013456A1 (en) * | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| KR20160025033A (en) * | 2013-02-20 | 2016-03-07 | 리제너론 파마슈티칼스 인코포레이티드 | Non-human animals with modified immunoglobulin heavy chain sequences |
-
2014
- 2014-09-18 WO PCT/US2014/056285 patent/WO2015042250A1/en active Application Filing
- 2014-09-18 CN CN201911266988.5A patent/CN111019953A/en active Pending
- 2014-09-18 DK DK14781761.3T patent/DK3046412T3/en active
- 2014-09-18 PT PT14781761T patent/PT3046412T/en unknown
- 2014-09-18 SG SG11201601272YA patent/SG11201601272YA/en unknown
- 2014-09-18 JP JP2016543984A patent/JP6621750B2/en active Active
- 2014-09-18 ES ES14781761T patent/ES2738679T3/en active Active
- 2014-09-18 RU RU2019121863A patent/RU2019121863A/en unknown
- 2014-09-18 AU AU2014323527A patent/AU2014323527B2/en active Active
- 2014-09-18 RS RS20190873A patent/RS59003B1/en unknown
- 2014-09-18 CN CN201480061443.XA patent/CN105722387B/en active Active
- 2014-09-18 EP EP14781761.3A patent/EP3046412B1/en active Active
- 2014-09-18 HU HUE14781761 patent/HUE044747T2/en unknown
- 2014-09-18 BR BR112016005912A patent/BR112016005912A2/en not_active IP Right Cessation
- 2014-09-18 LT LTEP14781761.3T patent/LT3046412T/en unknown
- 2014-09-18 KR KR1020167009721A patent/KR102150414B1/en active IP Right Grant
- 2014-09-18 MY MYPI2016700599A patent/MY191512A/en unknown
- 2014-09-18 TR TR2019/09967T patent/TR201909967T4/en unknown
- 2014-09-18 PL PL14781761T patent/PL3046412T3/en unknown
- 2014-09-18 ES ES19159475T patent/ES2962489T3/en active Active
- 2014-09-18 KR KR1020207024599A patent/KR20200103882A/en not_active Application Discontinuation
- 2014-09-18 MX MX2016003638A patent/MX362904B/en active IP Right Grant
- 2014-09-18 SI SI201431271T patent/SI3046412T1/en unknown
- 2014-09-18 CA CA2922892A patent/CA2922892C/en active Active
- 2014-09-18 EP EP19159475.3A patent/EP3549437B1/en active Active
- 2014-09-18 RU RU2016114306A patent/RU2694728C2/en active
- 2014-09-18 SG SG10201810825YA patent/SG10201810825YA/en unknown
-
2016
- 2016-02-22 IL IL244226A patent/IL244226B/en active IP Right Grant
- 2016-12-16 HK HK16114363A patent/HK1225913A1/en unknown
-
2019
- 2019-01-16 JP JP2019004905A patent/JP2019068850A/en not_active Withdrawn
- 2019-01-21 IL IL264358A patent/IL264358A/en unknown
- 2019-07-10 CY CY20191100728T patent/CY1121798T1/en unknown
- 2019-07-10 HR HRP20191233TT patent/HRP20191233T1/en unknown
-
2020
- 2020-03-03 JP JP2020035905A patent/JP2020078350A/en not_active Withdrawn
-
2021
- 2021-01-15 AU AU2021200228A patent/AU2021200228A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201810825YA (en) | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same | |
| MX355732B (en) | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same. | |
| SG194466A1 (en) | Non-human animals expressing antibodies having a common light chain | |
| IN2014DN08163A (en) | ||
| MX2015012540A (en) | Common light chain mouse. | |
| MX357308B (en) | Mice expressing a limited immunoglobulin light chain repertoire. | |
| HK1244219A1 (en) | Heterodimeric antibodies that bind cd3 and tumor antigens | |
| IL252480A0 (en) | Heterodimeric antibodies that bind cd3 and tumor antigens | |
| MX2022011659A (en) | Antigen binding proteins that bind pd-l1. | |
| MX2016012274A (en) | Non-human animals that make single domain binding proteins. | |
| IN2014CN03572A (en) | ||
| WO2013041845A3 (en) | Animals, repertoires & methods for the production of human antibodies | |
| MY178882A (en) | Non-human animals with modified immunoglobulin heavy chain sequences | |
| MX2014001454A (en) | Humanized universal light chain mice. | |
| MX2016009050A (en) | Bi-specific cd3 and cd19 antigen-binding constructs. | |
| MX2021010556A (en) | Non-human animals having an engineered immunoglobulin lambda light chain locus. | |
| MY194456A (en) | Mice expressing an immunoglobulin hybrid light chain | |
| DOP2013000129A (en) | PROTEINS OF UNION TO TNF-a. | |
| MX2018008701A (en) | Rodents having an engineered heavy chain diversity region. |